Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia
Introduction
Individuals with schizophrenia present with a constellation of signs and symptoms including positive and negative symptoms, and cognitive dysfunction (Tandon et al., 2009). Despite substantial development of treatments to address positive symptoms, treatments for cognitive impairment and negative symptoms have been more elusive (Kirkpatrick et al., 2006, Keefe et al., 2013). The significance of this question is underscored by the fact that these latter symptoms have been consistently linked to patients' functional outcome (Mohamed et al., 2008, Shamsi et al., 2011, Fervaha et al., 2014b).
The recent focus on cognitive functioning, especially in terms of its impact on outcomes, has resulted in increased interest in assessing this aspect of schizophrenia. There are numerous neuropsychological test batteries that may be administered to assess the degree of patients' cognitive impairment. Notably, the MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery (MCCB) represents the current “gold standard” among tools for the assessment of cognitive impairment, especially in the context of clinical trials evaluating the efficacy of cognition-enhancing agents (Nuechterlein et al., 2008, Buchanan et al., 2011). However, comprehensive batteries can be lengthy for both patients and examiners, potentially precluding its widespread use in situations where cognition would not be otherwise evaluated (e.g., routine clinical practice, research protocols not focused on cognition). The MCCB requires approximately 65 min of administration time. A brief assessment tool may offer some advantages in this regard by providing researchers and clinicians a means of rapidly evaluating the degree of global cognitive impairment in patients. However, it should be recognized that abbreviated batteries cannot (by definition) evaluate the full degree and profile of cognitive impairments. Nonetheless, knowledge of global impairment is relevant for both clinical and research purposes (e.g., patient characterization in research protocols).
Several abbreviated batteries have been proposed, such as the Brief Assessment of Cognition in Schizophrenia (BACS) (Keefe et al., 2004), the Repeatable Battery for the Assessment of Neuropsychological Scale (RBANS) (Gold et al., 1999), the Brief Cognitive Assessment (BCA) (Velligan et al., 2004), and the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS) (Hurford et al., 2011). These batteries do, in fact, require less administration time than more comprehensive batteries such as the MCCB, but it remains unclear whether the scores are comparable. Further, it is unknown whether scores from shorter batteries are related to clinically relevant variables, such as functioning, to a similar degree as scores from longer cognitive batteries within the same participants. This is a necessary feature for these batteries if they are to be employed in empirical research as a proxy for scores derived from more comprehensive batteries. Though it should be noted that scores from at least some of these abbreviated batteries are related to the functional status of patients with schizophrenia (Gold et al., 1999, Velligan et al., 2004, Keefe et al., 2006); however, whether the magnitude of this relationship is similar or different to the relationship found when scores derived from more comprehensive cognitive batteries are utilized is not clear.
In a previous study with schizophrenia patients we empirically established a brief neurocognitive assessment (BNA) tool, comprised of two cognitive tests that require up to 10 min of administration time, and showed that scores from the BNA were highly related to global cognition scores derived from a more comprehensive battery that takes about 90 min to administer (Fervaha et al., 2014a). We further demonstrated that global cognition scores, derived from either the BNA or the longer battery, were related to symptom severity and functional outcome, even in multivariate models, suggesting that scores from these two assessment tools are highly similar (Fervaha et al., 2014a). Given that the field has embraced the MCCB as the “gold standard” assessment tool for cognitive impairment in people with schizophrenia, it is important to know whether brief batteries first overlap with scores from the MCCB and, second and perhaps more importantly, show similar relationships with other clinical variables.
In this present study we sought to further examine the reliability and validity of the BNA by comparing and contrasting it with the MCCB. First, we examined the validity of the BNA in estimating global cognition scores by evaluating the amount of overlap with MCCB scores in patients with schizophrenia. Second, we extended this validation to healthy comparison subjects to examine if the BNA was valid in estimating global cognition in these participants as well. Third, we evaluated the test–retest reliability of the BNA and compared this with the MCCB. Finally, in order to establish the utility of the BNA, we compared the relationships between the BNA and important external variables such as symptom severity and functional capacity against the relationships between MCCB and the same external variables.
Section snippets
Participants
Data were drawn from the MATRICS Psychometric and Standardization Study (Kern et al., 2008, Nuechterlein et al., 2008). The objective of the MATRICS study was to create a cognitive battery that can be used in clinical trials evaluating cognition-enhancing agents in people with schizophrenia. Participants were recruited from 5 study sites (University of California Los Angeles, Duke University, Maryland Psychiatric Research Centre, Massachusetts Mental Health Centre, and University of Kansas).
Results
Demographic information for the patients and controls, as well as clinical data for the patients, is presented in Table 2.
Discussion
The present study sought to examine the reliability and validity of the BNA as a measure of global neurocognition. We found that the BNA had considerable overlap with the “gold standard” MCCB, suggesting that scores derived from the BNA can serve as a valid estimate of global neurocognition, and impairments therein. Notably, this high degree of overlap was found for both patients with schizophrenia and healthy control subjects. The BNA was also found to be sensitive to cognitive impairment in
Role of funding source
This work was supported, in part, by a Vanier Canada Graduate Scholarship (to G. Fervaha). Funding for the MATRICS initiative was provided through NIMH contract N01MH22006 to the University of California, Los Angeles. These funding sources had no further role in study design, statistical analysis or interpretation of findings; in writing of the manuscript; or in the decision to submit for publication.
Contributors
G. Fervaha conducted the statistical analyses, literature search and preparation of the first draft of the manuscript. All authors subsequently made meaningful contributions to and have approved the final manuscript.
Conflict of interest
R.S. Kern is an officer with MATRICS Assessment, Inc. and he receives financial compensation for his role in the non-profit organization. The other authors report no conflict of interest in relation to the present work.
Acknowledgments
We thank all participants for their participation in this study.
References (28)
- et al.
Toward a more parsimonious assessment of neurocognition in schizophrenia: a 10-minute assessment tool
J. Psychiatr. Res.
(2014) - et al.
Detecting reliable cognitive change in individual patients with the MATRICS Consensus Cognitive Battery
Schizophr. Res.
(2014) - et al.
Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS
Schizophr. Res.
(2004) - et al.
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria
Biol. Psychiatry
(2004) - et al.
The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery
Schizophr. Res.
(2004) - et al.
Identification of separable cognitive factors in schizophrenia
Schizophr. Res.
(2004) - et al.
Social cognition in schizophrenia: relationships with neurocognition and negative symptoms
Schizophr. Res.
(2007) - et al.
Cognitive and symptomatic predictors of functional disability in schizophrenia
Schizophr. Res.
(2011) - et al.
Schizophrenia, “just the facts” 4. Clinical features and conceptualization
Schizophr. Res.
(2009) - et al.
A brief cognitive assessment for use with schizophrenia patients in community clinics
Schizophr. Res.
(2004)
The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?
Schizophr. Bull.
Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia
Acta Psychiatr. Scand.
User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders SCID-I: Clinician Version
Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity
Am. J. Psychiatry
Cited by (23)
Montreal Cognitive Assessment (MoCA) and Digit Symbol Substitution Test (DSST) as a screening tool for evaluation of cognitive deficits in schizophrenia
2022, Psychiatry ResearchCitation Excerpt :The administration of these batteries takes around 90 min and would not be feasible for routine clinical evaluation in patients with schizophrenia (Nuechterlein et al., 2008; Kern et al., 2008). There are brief assessment tools such as the Brief Assessment of Cognition in Schizophrenia BACS (Keefe et al., 2004), Brief Cognitive Assessment Tool for Schizophrenia (B-CATS) (Hurford et al., 2011), Screen for cognitive impairment in psychiatry (SCIP) (Purdon, 2005) and Brief neurocognitive assessment (BNA) (Fervaha et al., 2015). But they are either too complex and/or time-consuming to suit the clinical needs or cover only a few cognitive domains to sensitively detect the heterogeneous pattern of deficits.
Peripheral biopterin and neopterin in schizophrenia and depression
2021, Psychiatry ResearchCitation Excerpt :Reward-related symptoms were assessed using the apathy or motivation and pleasure domain (sum score of avolition, asociality and anhedonia) of the Brief Negative Symptom Scale (BNSS) (Kirkpatrick et al., 2011). Cognition was assessed with the Brief Neurocognitive Assessment (BNA) (Fervaha et al., 2015). With the BNA, a cognitive score is computed for each participant by combining results from the Letter-Number-Span Test and the Symbol Coding Test.
Measurement based care in schizophrenia—Feasibility in routine clinical practice
2020, Asian Journal of PsychiatryMetacognition moderates the relationship between self-reported and clinician-rated motivation in schizophrenia
2020, Schizophrenia Research: CognitionInflexible social inference in individuals with subclinical persecutory delusional tendencies
2020, Schizophrenia Research